Multicenter Longitudinal Observational Study Pharmaceuticals Alflutop in Russia (message 2)

Osteoarthritis (OA) is one of the most important medical and social problems due to the steady increase in morbidity and disability. Prevention, management of risk factors, and early treatment of OA are critical.Objective of the ISKRA study was to evaluate the efficacy of Alflutop in patients with OA of different locations and/or low back pain (LBP) with or without concomitant diseases.Material and methods. We selected 11,136 patients with OA of specific localizations aged 50 to 72 years. The duration of the study ranged from 20 to 31 days, and the number of visits was 2 (B1 and B2). Alflutop was prescribed 1 ml intramuscularly (IM) daily No. 20 or 2 ml IM every other day No. 10.The efficacy of therapy was determined by the time of onset of clinical effect (pain reduction, as assessed by the patient), the dynamics of pain intensity in the studied joint during movement and/or LBP according to the visual analogue scale (VAS), the assessment of quality of life according to the EQ-5D questionnaire and the patient's general health status (PGH) according to VAS. We assessed treatment adherence, need for nonsteroidal anti-inflammatory drugs (NSAIDs), satisfaction with treatment (based on VAS). The presence of comorbidities was also considered.Results and discussion. In hand OA (n=2776), a positive effect of therapy was observed in 98.6% of cases, according to patients' assessment. During the course of therapy, there was a significant decrease in pain on movement in the hands (according to VAS), improvement in PGH and quality of life (according to EQ-5D). Rapid development of the analgesic effect was seen on average at day 9.In hip OA (n=6666), a decrease in pain was noted in 83.3% of cases (<40 mm), improvement in PGH and quality of life in most patients, and a decrease in the need for NSAIDs in 64.9%.In the generalized form of OA (n=1694), significant clinical improvement was achieved in 97.1% of patients. A pain reduction ≥50% from baseline was noted in nearly 65% of cases.Elderly age, more severe radiographic manifestations of OA, low quality of life and compliance, and concomitant diseases were associated with a lower effect of therapy in hand and hip OA. In hand OA, high pain scores and worse PGH VAS scores also played a role. In hip OA, lower success was observed more often in women, and in hand OA — in men.In the generalized form of OA, lower satisfaction with pain management was associated with age, female sex, high body mass index, long history of OA, advanced radiographic stages, poorer quality of life and compliance, and comorbidity.Conclusion. The results of the use of Alflutop in hand and hip OA and generalized form of OA suggest the usefulness of its wide application in real clinical practice. Consideration and correction of the factors associated with less pronounced analgesic effect of the drug will improve the effectiveness of OA therapy.

[1]  L. Vasilyeva,et al.  The role of chondroprotectors in the correction of pain in patients with osteoarthritis of the joints of the hands with Heberden’s nodes , 2022, Pharmateca.

[2]  Peng Cheng,et al.  Epidemiological trends of hand osteoarthritis from 1990 to 2019: Estimates from the 2019 Global Burden of Disease study , 2022, Frontiers in Medicine.

[3]  I. Ackerman,et al.  Global Burden of Disease Study 2019: an opportunity to understand the growing prevalence and impact of hip, knee, hand and other osteoarthritis in Australia , 2022, Internal medicine journal.

[4]  Qiang Liu,et al.  Prevalence Trends of Site‐Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019 , 2022, Arthritis & rheumatology.

[5]  A. Karateev Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials , 2020 .

[6]  V. Mazurov,et al.  A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens , 2020, Modern Rheumatology Journal.

[7]  G. Guyatt,et al.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee , 2020, Arthritis care & research.

[8]  J H Abbott,et al.  OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. , 2019, Osteoarthritis and cartilage.

[9]  J. Jordan,et al.  Defining multiple joint osteoarthritis, its frequency and impact in a community-based cohort. , 2019, Seminars in arthritis and rheumatism.

[10]  E. Taskina,et al.  Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment , 2019, Modern Rheumatology Journal.

[11]  Наталья Гаврииловна Кашеварова,et al.  Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение , 2019 .

[12]  А. Е. Филатова,et al.  Антикоагулянтная терапия и компоненты метаболического синдрома у пациентов с фибрилляцией предсердий в реальной амбулаторной клинической практике , 2019 .

[13]  Л. И. Алексеева,et al.  Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптом- и структурно-модифицирующего действия препарата алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 – оценка структурно- модифицирующего действия препарата , 2014, RSP 2014.

[14]  J. Jordan,et al.  "Generalized osteoarthritis": a systematic review. , 2014, Seminars in arthritis and rheumatism.

[15]  N. Shostak,et al.  MULTICENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFECT OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHROSIS. COMMUNICATION 1. EVALUATION OF THE SYMPTOM-MODIFYING EFFECT OF THE DRUG , 2013 .

[16]  P. Croft,et al.  Defining and mapping the person with osteoarthritis for population studies and public health , 2013, Rheumatology.

[17]  J A Sigidin,et al.  Алфлутоп в терапии остеоартроза , 2004 .

[18]  Hyoung-Woo Lee,et al.  Diagnosis and treatment of metabolic syndrome , 2006 .